## **Cancer and Bone Society Asia-Pacific Conference**

14:40-15:05 | Grand Hall 4+5, B1F

Symposium 2. The Evolving Landscape of Multiple Myeloma Bone Disease

# Youngil Koh

Professor Seoul National University Hospital (SNUH), Seoul, Korea

#### Career

2025.3-Current	Professor, Medical Oncology, SNUH, Seoul, Korea
2019.3-2025.4	Associate Professor, Hematology/Medical Oncology, SNUH, Seoul, Korea
2022.9-2024.5	Visiting Associate Professor, Department of Pathology, Stanford Univ. USA
2014.3-2019.2	Assistant Professor, Hematology/Medical Oncology, SNUH, Seoul, Korea
2013.5-2014.2	Clinical Fellow in Hematology/Medical Oncology, SNUH, Seoul, Korea
2010.3-2013.4	Public Service Doctor, Kkotdongnae, Gapyeong, Korea (Military service)
2010.2	Board Certified in Internal Medicine, SNUH, Seoul, Korea
2005.2	MD, Seoul National University College of Medicine, Seoul, Korea

#### Education

2018.2	PhD., Molecular and Clinical Oncology, Seoul National University, Seoul, Korea
2010.2	MS, Molecular and Clinical Oncology, Seoul National University, Seoul, Korea
2005.2	MD. Seoul National University College of Medicine, Seoul, Korea

#### • Qualification ID

Medical doctor, ID 86015 Internal Medicine, ID 12468

## GCP Training

2024.12 GCP training by Seoul National University Hospital

## Publication (1<sup>st</sup> or corresponding author only, including co-first author)

- 1. Koh Y, Lee HE, Im SA, et al. VEGF expression is related to good response and long progression—free survival in gastrointestinal stromal tumor patients treated with Sunitinib.

  Diagnostic molecular pathology: the American journal of surgical pathology, part B 2011;20:143–7.
- 2. Kim I, Koh Y, Yoon SS, et al. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients. American journal of hematology 2013;88:10–5.

### Curriculum Vitae

